PPMI

1 3 2 **SKIN BIOPSY ELIGIBILITY (PD - HC)** 1 4 0

SUBJECT ID | | | | | VISIT NO | | | |

INITIALS | | | | SITE NO | | | | VISIT DATE | | | MM | | DD | | | | | YYYY

A. ☐ Check box if subject signed consent to participate in the skin biopsy companion protocol.

B. Date informed consent for participation in skin biopsy companion protocol was signed: B. | | MM | | DD | | | | | YYYY

SUBJECT INCLUSION CRITERIA (0 = No, 1 = Yes)

1. Currently enrolled in the PPMI study 1. ☐

2. Is a subject with idiopathic PD, PD or unaffected subject with a LRRK2 or SNCA mutation, or is a healthy control subject in PPMI 2. ☐

3. Is able and willing to provide written informed consent in accordance with Good Clinical Practice(GCP), International Conference on Harmonization (ICH), and local regulations 3. ☐

4. Is able and willing to comply with study procedures 4. ☐

To be **ELIGIBLE** for study participation ALL items 1 - 4 must be 1 = YES

SUBJECT EXCLUSION CRITERIA (0 = No, 1 = Yes)

1. Has a history of keloid formation (unless keloid formation resulted from a skin biopsy that was required as part of routine medical care) 1. ☐

2. Is currently receiving treatment with anticoagulants (e.g., coumadin, heparin) that might preclude safe completion of a biopsy 2. ☐

3. Has a bleeding disorder that would preclude biopsy 3. ☐

4. In the investigator's judgement, any other reason that the individual should not participate (e.g., subject has an infectious disease or is in an immune compromised state (HIV, pregnancy, tuberculosis, etc.)) 4. ☐

To be **ELIGIBLE** for study participation **ALL** answers to items 1-4 must be **0 = No**